Author/Authors :
Negahdar, Feraidoon Cellular and Molecular Research Center - Faculty of Advanced Technologies in Medicine - Department of Anatomical Sciences - Iran University of Medical Sciences, Tehran , Mehdizadeh, Mehdi Cellular and Molecular Research Center - Faculty of Advanced Technologies in Medicine - Department of Anatomical Sciences - Iran University of Medical Sciences, Tehran , Joghataei, Mohammad Taghi Cellular and Molecular Research Center - Faculty of Advanced Technologies in Medicine - Department of Anatomical Sciences - Iran University of Medical Sciences, Tehran , Roghani, Mehrdad Neurophysiology Research Center - Shahed University, Tehran , Mehraeen, Fereshteh Cellular and Molecular Research Center - Faculty of Advanced Technologies in Medicine - Department of Anatomical Sciences - Iran University of Medical Sciences, Tehran , Poorghayoomi, Ehsan Cellular and Molecular Research Center - Faculty of Advanced Technologies in Medicine - Department of Anatomical Sciences - Iran University of Medical Sciences, Tehran
Abstract :
Parkinson’s disease (PD) is a rather common movement disorder as a result of the
degeneration of dopaminergic neurons within the substantianigra. Current treatments for PD afford symptomatic relief with no prevention of disease progression. Due to the neuroprotective and anti-apoptotic potential of the isoquinoline alkaloid berberine (BBR), this study was conducted to assess whether BBR pretreatment could attenuate behavioral and neuronal derangement in 6-hydroxydopamine (6-OHDA)-induced model of PD in the rat. Unilateral intrastriatal 6-OHDA-lesioned rats received BBR at doses of 25 and/or 50 mg/kg (i.p.) three times at an interval of 24 h, started 2 days before the surgery. After 1 week, apomorphine caused significant contralateral rotations and a significant reduction in the number of Nisslstained and tyrosine-hydroxylase (TH)-positive neurons on the left side of the substantianigra. BBR pretreatment at a dose of 50 mg/kg significantly reduced rotations and prevented loss of TH-positive neurons. These results indicate pre-lesion administration of BBR could protect against 6-OHDA toxicity and this may be of benefit besides other available therapies in PD.
Keywords :
Berberine , Parkinson’s disease , 6-hydroxydopamine , Tyrosine hydroxylase